Global DNA Analysis in the Government Sector Market 2015-2019 – Biotechnology, Healthcare Industries

The Global DNA Analysis in the Government Sector Market 2015-2019 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare Markets.

Overview of the global DNA analysis market

The adoption of mobile applications for DNA analysis is a key trend in the global DNA analysis market. Market research analysts project a market growth rate of close to 14% until 2019.

It is used for purposes that include identifying criminals involved on charges of homicide. DNA analysis is also being used to identify victims of natural calamities and troops on the battlefield. Another application of DNA analysis is in the field of decoding familial relationships of individuals.

As there are few vendors in the market, the cost involved in conducting DNA analysis is steep. However, in the forecast period, with an increase in the number of vendors entering this market, the cost of DNA analysis is expected to decline.

Global DNA analysis market in government sector by application

– Defense
– Homeland security

The homeland security sector is expected to witness a steady growth rate during the forecast period. The use of DNA biometrics for individual will soon be required for embedding in passports for immigration purposes. The market share of the defense sector will witness a decline during the forecast period due to the adoption of cost-effective biometric technologies such as iris recognition for identity verification.

Global DNA analysis market in government sector by application

– Law enforcement
– Forensics

The market share of forensics is expected to increase during the forecast period due to the increasing prevalence of DNA sampling to identify criminals. However, the adoption of DNA analysis for law enforcement purposes is expected to be slow, thus, it has a declining market share.

Global DNA analysis in government sector by geographical segmentation

– MEA
– Latin America
– APAC
– Europe
– North America

Vendor landscape of the global DNA analysis market

– Lockheed Martin
– M2SYS
– NEC
– Safran

Currently, a number of vendors are investing in R&D to develop mobile applications such as DNAApp that allows DNA analysis on mobile devices. This application is available freely on Google Play store and Apple app store, and can be run easily on platforms such as Windows and MAC. These developments are expected to decode and display results on operating systems such as Android and iOS.

Key questions answered in the report

– What are the key factors driving the global DNA analysis market in the government sector?
– What are the key market trends impacting the growth of the global DNA analysis market in the government sector?
– What are the various opportunities and threats faced by the vendors in the global DNA analysis market in the government sector?
– Trending factors influencing the market shares for the global DNA analysis market in the government sector?
– Market shares for APAC, Americas, and EMEA?
– Key outcome of the five forces analysis on the global DNA analysis market in the government sector?
– Growth forecast of the global DNA analysis market in the government sector?

Related reports

– Global Medical Specialty Bags Market: Research Report 2015-2019
– Global Implantable Medical Devices Market 2015-2019- Market Analysis
– Global Medical Transcription Market 2015-2019
– Global Medical Electrodes Market 2015-2019

Read more and order at Global DNA Analysis in the Government Sector Market 2015-2019

Global and Chinese PMSF (CAS 329-98-6) Industry – 2016 – Biotechnology, Healthcare, Proteomics Industries

The Global and Chinese PMSF (CAS 329-98-6) Industry – 2016 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Proteomics Markets.

The 'Global and Chinese PMSF Industry, 2016 Market Research Report' is a professional and in-depth study on the current state of the global PMSF industry with a focus on the Chinese market. The report provides key statistics on the market status of the PMSF manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of PMSF industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2016-2021 market development trends of PMSF industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of PMSF Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese PMSF industry covering all important parameters.

PLEASE NOTE: This report will be completed after order and will take approximately 2-3 business days after the confirmation of payment.

Read more and order at Global and Chinese PMSF (CAS 329-98-6) Industry – 2016

Biomedical Materials Drug Delivery, Implants, and Tissue Engineering: Volume 550. MRS Proceedings – Biomaterials, Biotechnology, Healthcare Industries

The Biomedical Materials Drug Delivery, Implants, and Tissue Engineering: Volume 550. MRS Proceedings Report has been published. It provides updated in 2018 year analysis of industries from Biomaterials, Biotechnology, Healthcare Markets.

The continual growth and increasing sophistication of biomaterials industries has been driven in large part by advances in the basic sciences of the materials involved. Indeed, advances in understanding biological systems at the molecular level have quickly been exploited by materials scientists to develop more sophisticated approaches to therapeutics and diagnostics. The interdisciplinarity and breadth of the biomaterials field necessitates the close co-operation of scientists in many different fields, including materials science, chemistry, biology, engineering and medicine. This book, first published in 1999, brings together researchers in many of these converging fields to report on advances and to stimulate further discussion and research in these vital areas of discovery and development. Topics include: polymeric drugs and delivery; musculoskeletal tissue engineering; scaffolds and cell seeding – fabrication and characterization techniques; biological cues and organic/inorganic hybrids; novel materials, porous structure and tissue engineering; and orthopaedic bearing surfaces and novel coatings.

Read more and order at Biomedical Materials Drug Delivery, Implants, and Tissue Engineering: Volume 550. MRS Proceedings

Neural Degeneration and Repair. Gene Expression Profiling, Proteomics and Systems Biology – Biotechnology, Genomics, Healthcare Industries

The Neural Degeneration and Repair. Gene Expression Profiling, Proteomics and Systems Biology Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Genomics, Healthcare Markets.

With contributions from leading scientists around the world, this is the first book focussing on the analysis of nerve cell damage and repair using genomics, transcriptomics, proteomics and systems biology in order to develop novel therapeutic and diagnostic approaches for neural diseases.

Following an introduction into the microarray technology in translational neuroscience, the book goes on to look at the use of ′–omics′ technologies to analyse molecular changes in traumatic injury, neuron degeneration and regeneration, oxidative stress response, neuropathic pain manifestation etc. The work covers central nervous system as well as peripheral nervous system pathologies. This novel approach makes the book an indispensable companion for neurobiologists, neurologists, cell and molecular biologists, geneticists, and analytical chemists.

Read more and order at Neural Degeneration and Repair. Gene Expression Profiling, Proteomics and Systems Biology

Global and Chinese Monooxygenase Enzyme Industry – 2017 – Biotechnology, Enzymes, Healthcare Industries

The Global and Chinese Monooxygenase Enzyme Industry – 2017 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Enzymes, Healthcare Markets.

The 'Global and Chinese Monooxygenase Enzyme Industry – 2017' is a professional and in-depth study on the current state of the global Monooxygenase Enzyme industry with a focus on the Chinese market. The report provides key statistics on the market status of the Monooxygenase Enzyme manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of the Monooxygenase Enzyme industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of the Monooxygenase Enzyme industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of the Monooxygenase Enzyme Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Monooxygenase Enzyme industry covering all important parameters.

PLEASE NOTE: This report will be completed after order and will take approximately 2-3 business days after the confirmation of payment.

Read more and order at Global and Chinese Monooxygenase Enzyme Industry – 2017

Biophotonics Market by Medical Applications (Bioimaging, Bioassays, Optical Biosensors and Biochips, Medical Devices), Non-Medical Applications (Biometric and Biosensing Devices, Uv Sterilization Equipment), and Regions – Global Forecast To 2020 – Biotechnology, Healthcare Industries

The Biophotonics Market by Medical Applications (Bioimaging, Bioassays, Optical Biosensors and Biochips, Medical Devices), Non-Medical Applications (Biometric and Biosensing Devices, Uv Sterilization Equipment), and Regions – Global Forecast To 2020 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare Markets.

The overall market for biophotonics in 2014 was valued at USD 26.26 Billion, which is estimated to reach USD 50.18 Billion by 2020, at a CAGR of 11.5% during the forecast period. This market growth can be attributed to emergence of nanotechnology, significant technological advancements over the last few years and their adoption in the medical sector, increase in the demand for home-based POC devices, aging population, and growing lifestyle diseases. The report categorizes the global biophotonics market on the basis of application, technology, end use, and geography as well as forecasts the market size and analyzes trends in the said market. This report is focused on giving a bird’s eye-view of the market with regards to the qualitative analysis at each and every aspect of the classification done. The report provides a forecast of the growth of the biophotonics market between 2015 and 2020.

This research study involves extensive usage of secondary sources, directories, and databases (such as Hoovers, Bloomberg, Businessweek, Factiva, and OneSource) to identify and collect information useful for this technical, market-oriented, and commercial aspects of biophotonics market. In addition to secondary sources, the market data was collected by primary research as well by conducting extensive interviews with key people such as CEOs, VPs, Directors and executives. After arriving at the overall market size the total market has been split into several segments and sub-segments. The figure below shows the break-down of the primaries on the basis of company, designation, and region, conducted during the research study.

This report takes a close look at the biophotonics market, providing a holistic outlook on market dynamics, industry trends, and supply & demand. The study aims at providing granular information regarding estimates and forecasts for the biophotonics market segments. This report is based on an extensive research study of the biophotonics market and aims at identifying the entire market and all its sub-segments through extensively detailed classifications. The demand for biophotonics is expected to grow significantly and gain importance among players across various domains. The Americas is projected to be the fastest-growing market during the forecast period.

The information provided in this report includes profiles of leading companies in the biophotonics ecosystem, key developments, core strategies deployed by various players, mergers and acquisitions, new product developments, collaborations, and joint ventures of key manufacturers along with their financials. A competitive landscape of the current market has been analyzed on the basis of a company’s recent developments, R&D activities, and product portfolio among other factors.

The target audience of the report include existing players in biophotonics market, start-up companies, venture capitalists, private equity groups, investment houses, equity research firms and other stakeholders. This study answers several questions for the stakeholders, primarily which market segments to focus in next two to five years for prioritizing the efforts and investments.

The report also discusses the future of the global market with roadmaps, upcoming technologies, and applications with respect to biophotonics market. Key players in this industry include, Affymetrix, Inc. (U.S.), Andor Technology Ltd. (U.K.), Becton, Dickinson and Company (U.S.), Carl Zeiss AG (Germany), FEI Company (U.S.), Hamamatsu Photonics K.K. (Japan), Lumenis Ltd. (Israel), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), and Zecotek Photonics Inc. (Canada).

Read more and order at Biophotonics Market by Medical Applications (Bioimaging, Bioassays, Optical Biosensors and Biochips, Medical Devices), Non-Medical Applications (Biometric and Biosensing Devices, Uv Sterilization Equipment), and Regions – Global Forecast To 2020

Cytogenetics – Technologies Markets and Companies – Biotechnology, Genomics, Healthcare Industries

The Cytogenetics – Technologies Markets and Companies Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Genomics, Healthcare Markets.

This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.

FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described.

Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects.

Technologies encompassed within molecular imaging include optical imaging, magnetic resonance imaging (MRI) and nuclear medicine techniques. Positron emission tomography (PET) is the most sensitive and specific technique for imaging molecular pathways in vivo in humans. Cytogenetics can be refined by application of cytogenetics at single molecule level. Nanotechnology has facilitated the development of technology for single molecule imaging. Atomic force microscope (AFM) has become a well-established technique for imaging single biomolecules under physiological conditions. The scanning probe microscope (SPM) system is emerging as an increasingly important tool for non-intrusive interrogation of biomolecular systems in vitro and have been applied to improve FISH. Another example of application of nanobiotechnology is QD (quantum dot)-FISH probes, which can detect down to the single molecule level.

There are connections between cytogenetics and biomarkers of genetic disorders as well as cancer. Biomarkers are very important for molecular diagnostics. Not only are molecular diagnostic technologies used for discovery of biomarkers, biomarkers are the basis of several diagnostics. As a means to understand pathomechanism of disease and as links between diagnostics and therapeutics, biomarkers are playing a role in development of personalized medicine. Application of cytogenetics extend beyond genetic disorder and cancer to diagnosis of several other diseases. Other important applications are drug discovery, and development of personalized medicine.

The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan. The total figures for the market are also broken out according to the technologies and major disease areas in which they are applied. Markets figure are given for the year 2016 and estimates are made for the years 2021 and 2026. Advantages and limitations of various technologies have been pointed out throughout the report but this chapter includes SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of some of the competing technologies including the following: conventional FISH, innovative FISH technologies, PCR-based assays, and single molecule imaging. Unfulfilled needs in cytogenetics market are depicted graphically. Among various technologies, FISH is most advanced and less opportunities for further development than single molecule detection, which is in infancy and has more future potential.

The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography.

The following areas are covered in this report:

  • Introduction to cytogenetics
  • Technologies used for cytogenetics
  • Fluorescent in situ hybridization
  • Genomic technologies relevant to cytogenetics
  • Molecular imaging and single molecular detection
  • Role of nanobiotechnology in cytogenetics
  • Biomarkers and cytogenetics
  • Applications of cytogenetics
  • Cancer cytogenetics
  • Markets for cytogenetics
  • Companies

Read more and order at Cytogenetics – Technologies Markets and Companies

MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) – Pipeline Review, H1 2016 – Biotechnology, Enzymes, Healthcare Industries

The MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) – Pipeline Review, H1 2016 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Enzymes, Healthcare Markets.

MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) – Pipeline Review, H1 2016

Summary

‘MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) – Pipeline Review, H1 2016’, provides in depth analysis on MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1)
– The report reviews MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
– The report assesses MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) – Pipeline Review, H1 2016

Carbonic Anhydrase 2 (CA2) Inhibitors – Pipeline Insights, 2017 – Biotechnology, Enzymes, Healthcare Industries

The Carbonic Anhydrase 2 (CA2) Inhibitors – Pipeline Insights, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Enzymes, Healthcare Markets.

“Carbonic Anhydrase 2 (CA2) Inhibitors – Pipeline Insights, 2017” provides in depth insights on the pipeline drugs and their development activities around the Carbonic Anhydrase 2 (CA2) Inhibitors. The This report covers the product profiles in various stages of development including Discovery, Pre – clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Carbonic Anhydrase 2 (CA2) Inhibitors. This report also assesses the Carbonic Anhydrase 2 (CA2) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up – to – date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:

  • The report provides competitive pipeline landscape of Carbonic Anhydrase 2 (CA2) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Carbonic Anhydrase 2 (CA2) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Carbonic Anhydrase 2 (CA2) Inhibitors and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time: 2 Working Days.

Read more and order at Carbonic Anhydrase 2 (CA2) Inhibitors – Pipeline Insights, 2017

Europe Cancer Biomarkers Market – Growth, Trends and Forecasts – Biomarkers, Biotechnology, Healthcare Industries

The Europe Cancer Biomarkers Market – Growth, Trends and Forecasts Report has been published. It provides updated in 2018 year analysis of industries from Biomarkers, Biotechnology, Healthcare Markets.

Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening.

Major factors for the Europe biomarkers market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field.

European biomarkers market is segmented based on type of applications, By services. Global Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market.

Major companies covered in this market are Roche Diagnostics Limited (Switzerland),GlaxoSmithKline, Plc. (U.K.),Siemens Healthcare (Germany),Epigenomics AG (Germany).

Companies Featured

1) Roche Applied Science

2) Bio-Rad

3) Qiagen

What makes our report Unique?

1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market.

2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing)

3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.

Read more and order at Europe Cancer Biomarkers Market – Growth, Trends and Forecasts